Which oral hypoglycaemic agents (OHAs) can cause hypoglycemia?

Oral Hypoglycemic Agents That Cause Hypoglycemia

Sulfonylureas and meglitinides are the primary oral hypoglycemic agents that cause hypoglycemia, with sulfonylureas carrying the highest risk among all oral agents. 1

High-Risk Agents

Sulfonylureas (Highest Risk)

• Sulfonylureas are associated with the highest risk of hypoglycemia among all oral antidiabetic medications, with an adjusted odds ratio of 10.13 compared to other agents 2
• These agents stimulate insulin secretion from pancreatic β-cells regardless of glucose levels, creating inherent hypoglycemia risk 1
• First-generation sulfonylureas (chlorpropamide, tolazamide, tolbutamide) should be avoided entirely, especially in patients with chronic kidney disease, due to prolonged half-lives and accumulation of active metabolites 1
• Among second-generation agents, glyburide (glibenclamide) carries the highest hypoglycemia risk and is considered problematic 3, 4
• Glipizide and gliclazide are preferred second-generation options as they lack active metabolites and pose lower hypoglycemia risk 1
• Risk increases 50% when sulfonylureas are combined with DPP-4 inhibitors 1

Meglitinides (Moderate Risk)

• Meglitinides (repaglinide, nateglinide) cause hypoglycemia but at lower rates than sulfonylureas, with an adjusted OR of 3.17 2
• These short-acting insulin secretagogues stimulate early-phase insulin secretion 1
• Nateglinide accumulates active metabolites in renal insufficiency, while repaglinide does not 1
• When combined with gemfibrozil, repaglinide concentrations and half-life increase significantly, requiring dose reduction to avoid hypoglycemia 1

Low-Risk or No-Risk Agents

Minimal to No Hypoglycemia Risk

• Metformin does not cause hypoglycemia when used alone 1
• Thiazolidinediones (pioglitazone, rosiglitazone) do not cause hypoglycemia as monotherapy 1, 2, 3
• α-Glucosidase inhibitors (acarbose, voglibose, miglitol) have very low hypoglycemia risk when used alone 1, 2
• DPP-4 inhibitors have minimal hypoglycemia risk as monotherapy 1, 2, 5
• GLP-1 receptor agonists have minimal hypoglycemia risk due to glucose-dependent insulin secretion 1
• SGLT2 inhibitors consistently reduce severe hypoglycemia compared to usual care 1

Critical Clinical Considerations

Combination Therapy Risks

• Any low-risk agent combined with sulfonylureas or insulin increases hypoglycemia risk substantially 1
• Metformin plus sulfonylurea combinations increase hypoglycemia incidence compared to metformin alone 1
• Thiazolidinediones combined with sulfonylureas or insulin considerably increase hypoglycemia risk despite TZDs' inherent safety profile 1, 3

Special Populations at Higher Risk

• Patients with CKD stages 3-5 have markedly increased hypoglycemia risk due to decreased drug clearance and impaired renal gluconeogenesis 1
• Elderly patients are especially susceptible to hypoglycemia and require particular caution 1, 3
• Patients with liver dysfunction, alcoholism, or malnutrition face elevated hypoglycemia risk 3, 4

Clinical Impact

• Hypoglycemia is associated with significantly increased healthcare costs (+$5,024 annual all-cause costs, +$3,747 diabetes-related costs) 5
• Experiencing hypoglycemic events significantly increases the risk of antidiabetic treatment discontinuation 5
• Hypoglycemia requiring assistance occurs at an estimated frequency of 0.054 events per patient-year across all oral agents 5